Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.

Détails

ID Serval
serval:BIB_73DC47A54E2B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.
Périodique
Expert review of anticancer therapy
Auteur(s)
Skafida E., Kokkali S., Nikolaou M., Digklia A.
ISSN
1744-8328 (Electronic)
ISSN-L
1473-7140
Statut éditorial
Publié
Date de publication
06/2017
Peer-reviewed
Oui
Volume
17
Numéro
6
Pages
537-543
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinical stage development demonstrating to be effective in controlled studies. While these novel treatments can be beneficial to a subset of patients, even producing long lasting remissions, a significant fraction of the STS population derives limited benefit. This is due to the fact that STS is a very heterogeneous disease with different histopathologic features, biological characteristics and clinical behaviour. Areas covered: The primary aim of this review is to summarize data from recent phase III clinical trials in unselected STS population, and to discuss their impact on the current clinical practice. Phase I-II trials of special interest are discussed as well. Expert commentary: Although our efforts in this research task are ongoing, the integration of biological therapies, the anti-angiogenesis targeted treatments as well as immunotherapy that may further improve the long term control of advanced STS are of special clinical interest. Clinical management of advanced STS should be tailored to each patient in order to optimize therapy.

Mots-clé
Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/pharmacology, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/pharmacology, Drug Design, Humans, Immunotherapy/methods, Molecular Targeted Therapy, Neoplasm Metastasis, Sarcoma/drug therapy, Sarcoma/pathology
Pubmed
Web of science
Création de la notice
29/04/2017 17:22
Dernière modification de la notice
03/03/2018 18:20
Données d'usage